CompletedPhase 4NCT01521715

First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma

Studying Acquired cystic disease-associated renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
iOMEDICO AG
Principal Investigator
Michael Staehler, PD MD
Ludwig-Maximilians-Universität München, Klinikum Grosshadern
Intervention
Pazopanib(drug)
Enrollment
44 enrolled
Eligibility
18 years · All sexes
Timeline
20122017

Study locations (8)

Collaborators

Novartis Pharmaceuticals

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01521715 on ClinicalTrials.gov

Other trials for Acquired cystic disease-associated renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Acquired cystic disease-associated renal cell carcinoma

← Back to all trials